PL2289879T3 - Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu - Google Patents
Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamiduInfo
- Publication number
- PL2289879T3 PL2289879T3 PL10180395T PL10180395T PL2289879T3 PL 2289879 T3 PL2289879 T3 PL 2289879T3 PL 10180395 T PL10180395 T PL 10180395T PL 10180395 T PL10180395 T PL 10180395T PL 2289879 T3 PL2289879 T3 PL 2289879T3
- Authority
- PL
- Poland
- Prior art keywords
- methylpropyloxy
- methylpiperidin
- fluorobenzyl
- phenylmethyl
- synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61401404P | 2004-09-27 | 2004-09-27 | |
EP10180395.5A EP2289879B1 (en) | 2004-09-27 | 2005-09-26 | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
EP05805643A EP1794126B1 (en) | 2004-09-27 | 2005-09-26 | Crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2289879T3 true PL2289879T3 (pl) | 2015-05-29 |
Family
ID=35539440
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10180395T PL2289879T3 (pl) | 2004-09-27 | 2005-09-26 | Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu |
PL05805643T PL1794126T3 (pl) | 2004-09-27 | 2005-09-26 | Postać krystaliczna półwinianu N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylo-propyloksy)-fenylometylo)karbamidu |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05805643T PL1794126T3 (pl) | 2004-09-27 | 2005-09-26 | Postać krystaliczna półwinianu N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylo-propyloksy)-fenylometylo)karbamidu |
Country Status (18)
Country | Link |
---|---|
US (6) | US7732615B2 (pl) |
EP (3) | EP1794125A1 (pl) |
JP (2) | JP5154227B2 (pl) |
KR (2) | KR101260036B1 (pl) |
CN (3) | CN101031548B (pl) |
AU (2) | AU2005289444B2 (pl) |
BR (1) | BRPI0516063A (pl) |
CA (2) | CA2580136C (pl) |
DK (1) | DK1794126T3 (pl) |
ES (2) | ES2530258T3 (pl) |
HK (1) | HK1102397A1 (pl) |
MX (2) | MX2007003403A (pl) |
NZ (1) | NZ553702A (pl) |
PL (2) | PL2289879T3 (pl) |
RU (2) | RU2417986C2 (pl) |
SG (2) | SG157378A1 (pl) |
WO (2) | WO2006036874A1 (pl) |
ZA (3) | ZA200702345B (pl) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4664564B2 (ja) * | 2000-03-06 | 2011-04-06 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン関連疾患の治療に使用する含窒素環式化合物 |
MXPA04006280A (es) * | 2001-12-28 | 2004-09-27 | Acadia Pharm Inc | Compuestos espiroazaciclicos como moduladores de receptor de monoamina. |
RU2320646C2 (ru) * | 2002-06-24 | 2008-03-27 | Акадиа Фармасьютикалз Инк. | N-замещенные производные пиперидина в качестве агентов серотонинового рецептора |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) * | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
SG170617A1 (en) | 2003-01-16 | 2011-05-30 | Acadia Pharm Inc | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
SG157378A1 (en) | 2004-09-27 | 2009-12-29 | Acadia Pharm Inc | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
WO2007124136A1 (en) * | 2006-04-19 | 2007-11-01 | Acadia Pharmaceuticals, Inc. | Use of 4-amino-piperidines for treating sleep disorders |
CA2652300A1 (en) * | 2006-05-15 | 2007-11-22 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
PL2134330T3 (pl) | 2007-03-19 | 2013-10-31 | Acadia Pharm Inc | Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami |
US20080280886A1 (en) * | 2007-05-08 | 2008-11-13 | Auspex Pharmaceuticals, Inc. | Substituted ureas |
JP2010527938A (ja) * | 2007-05-18 | 2010-08-19 | アカドイア プハルマセウチカルス インコーポレーテッド | パーキンソン病およびその症候の治療におけるピマバンセリンの使用 |
US20090082342A1 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
AU2008302079A1 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | Co-administration of pimavanserin with other agents |
AU2009267159B2 (en) * | 2008-06-30 | 2014-05-15 | Janssen Pharmaceutica Nv | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
AR091507A1 (es) * | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
WO2014085362A1 (en) | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
ES2894770T3 (es) * | 2013-06-21 | 2022-02-15 | Intra Cellular Therapies Inc | Cristales de base libre |
JP2015117192A (ja) * | 2013-12-17 | 2015-06-25 | 東和薬品株式会社 | シロドシンγ型結晶及びその製造方法 |
CN104961671B (zh) * | 2014-09-05 | 2018-01-02 | 苏州晶云药物科技有限公司 | N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法 |
EP3271018B1 (en) | 2015-03-02 | 2020-12-23 | Pliva Hrvatska D.O.O. | Processes and intermediates for the preparation of pimavanserin |
CN104961672B (zh) * | 2015-05-20 | 2017-10-20 | 沈阳药科大学 | 一种n‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑异丁氧基苄基)脲的酒石酸盐的合成方法 |
CN104844502B (zh) * | 2015-06-05 | 2018-07-31 | 齐鲁师范学院 | 一种匹莫范色林的制备方法 |
PL3325444T3 (pl) | 2015-07-20 | 2021-12-06 | Acadia Pharmaceuticals Inc. | Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C |
CZ2015601A3 (cs) | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
CN105111135A (zh) * | 2015-09-09 | 2015-12-02 | 安徽省逸欣铭医药科技有限公司 | 取代的尿素衍生物制备方法 |
CZ2015688A3 (cs) | 2015-10-02 | 2017-04-12 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů |
CN105153016B (zh) * | 2015-10-12 | 2017-10-03 | 北京诺康达医药科技有限公司 | 一种匹莫范色林的制备方法 |
CN106588753B (zh) * | 2015-10-19 | 2021-07-09 | 重庆医药工业研究院有限责任公司 | 一种制备匹马色林的方法 |
CN106699637A (zh) * | 2015-11-17 | 2017-05-24 | 重庆医药工业研究院有限责任公司 | 一种匹马色林单酒石酸盐晶型及其制备方法 |
CN105924381B (zh) * | 2015-12-18 | 2019-04-16 | 重庆两江药物研发中心有限公司 | 一种哌马色林晶型c的制备方法 |
CN105481757A (zh) * | 2015-12-25 | 2016-04-13 | 北京康立生医药技术开发有限公司 | 一种哌马色林的制备方法 |
CN105523993A (zh) * | 2015-12-28 | 2016-04-27 | 重庆两江药物研发中心有限公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用 |
CN107021917B (zh) * | 2016-02-02 | 2020-08-04 | 江苏恩华药业股份有限公司 | 哌马色林半酒石酸盐的新晶型及其制备方法 |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
EP3436010B1 (en) | 2016-03-29 | 2021-03-10 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
CN105820110B (zh) * | 2016-05-09 | 2018-07-24 | 杭州科巢生物科技有限公司 | 匹莫范色林合成方法 |
WO2018049836A1 (zh) | 2016-05-19 | 2018-03-22 | 上海诚妙医药科技有限公司 | 匹莫范色林酒石酸盐的新晶型及其制备方法和用途 |
CN105859608B (zh) * | 2016-05-27 | 2018-12-28 | 成都百裕制药股份有限公司 | 一种制备哌马色林半酒石酸盐晶型b的方法 |
HU231097B1 (hu) * | 2016-07-08 | 2020-08-28 | Egis Gyógyszergyár Zrt. | Gyógyászati készítmény előállítására alkalmazható pimavanserin sók |
KR102355955B1 (ko) * | 2016-09-23 | 2022-01-25 | 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 | 퀴나졸린 유도체의 염, 이의 제조 방법 및 응용 |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
US20180208556A1 (en) | 2017-01-20 | 2018-07-26 | Sci Pharmtech, Inc. | Method for Preparing Pimavanserin |
CN106916098A (zh) * | 2017-03-07 | 2017-07-04 | 江苏艾立康药业股份有限公司 | 一种哌马色林单酒石酸盐半水合物及制备方法 |
EP3615028A1 (en) | 2017-04-28 | 2020-03-04 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
EP3630103A4 (en) | 2017-05-25 | 2021-04-14 | Glytech LLC. | COMBINATION THERAPY FOR NMDAR ANTAGONIST RESPONDING NEUROPSYCHIATRIC DISEASES |
CN107216271B (zh) * | 2017-06-02 | 2018-11-13 | 沈阳药科大学 | 酒石酸匹莫范色林杂质及其制备方法 |
CA3067162A1 (en) | 2017-06-12 | 2018-12-20 | Glytech Llc. | Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists |
US11440884B2 (en) | 2017-08-21 | 2022-09-13 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and methods for treatment of diseases |
BR112020003477A2 (pt) * | 2017-08-21 | 2020-08-25 | Acadia Pharmaceuticals, Inc. | compostos e método para tratar uma doença |
WO2019046167A1 (en) | 2017-08-30 | 2019-03-07 | Acadia Pharmaceuticals Inc. | PIMAVANSERIN FORMULATIONS |
JP2018035199A (ja) * | 2017-12-07 | 2018-03-08 | 東和薬品株式会社 | シロドシンγ型結晶及びその製造方法 |
CN111201218A (zh) * | 2017-12-22 | 2020-05-26 | 广东东阳光药业有限公司 | 一种哌马色林半酒石酸盐的新晶型及其制备方法 |
IT201800003736A1 (it) | 2018-03-19 | 2019-09-19 | Lundbeck Pharmaceuticals Italy S P A | Processo per la produzione di Pimavanserin |
IT201800009690A1 (it) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | Processo per la produzione di pimavanserina |
US20220016101A1 (en) | 2018-10-30 | 2022-01-20 | Acadia Pharmaceuticals Inc. | Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin |
CN111320568B (zh) * | 2018-12-15 | 2021-12-07 | 浙江京新药业股份有限公司 | 一种匹莫范色林的新晶型及其制备方法 |
WO2021016369A1 (en) | 2019-07-22 | 2021-01-28 | Acadia Pharmaceuticals Inc. | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder |
WO2021030607A1 (en) | 2019-08-15 | 2021-02-18 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating neurodegenerative diseases |
CA3155542A1 (en) * | 2019-11-08 | 2021-05-14 | Kwok YAU | Amorphous form of a complement component c5a receptor |
BR112022007488A2 (pt) | 2019-11-08 | 2022-07-12 | Chemocentryx Inc | Forma cristalina de base livre de um receptor c5a de componente do complemento |
US11427541B2 (en) | 2019-11-08 | 2022-08-30 | Chemocentryx, Inc. | Salt forms of a complement component C5A receptor |
CN113214231B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其医疗应用 |
WO2022094230A1 (en) | 2020-11-02 | 2022-05-05 | Acadia Pharmaceuticals Inc. | Compounds for treating psychosis or depression |
CN112920108A (zh) * | 2021-01-29 | 2021-06-08 | 北京诺康达医药科技股份有限公司 | 酒石酸匹莫范色林晶型a的制备方法 |
CN114874103B (zh) * | 2022-05-11 | 2024-09-06 | 合肥立方制药股份有限公司 | 一种匹莫范色林中间体4-异丁氧基苄胺的连续合成方法 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE794333A (fr) | 1972-01-20 | 1973-07-19 | Wyeth John & Brother Ltd | Composes heterocycliques azotes therapeutiques |
GB1507462A (en) | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
US3983234A (en) | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
GB1586468A (en) * | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
CA1140119A (en) | 1978-04-03 | 1983-01-25 | Joseph Torremans | N-heterocyclyl-4-piperidinamines |
US4255432A (en) | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353901A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
GB8527052D0 (en) | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
GB8621892D0 (en) | 1986-09-11 | 1986-10-15 | Lundbeck & Co As H | Organic compound |
FR2642069B1 (fr) | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5214055A (en) | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
US5216165A (en) | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
IT1252227B (it) | 1991-12-17 | 1995-06-05 | Ciba Geigy Spa | Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
JPH09501404A (ja) | 1993-05-26 | 1997-02-10 | スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク | 新規化合物 |
US5707798A (en) | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
DE4404183A1 (de) | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
NZ320963A (en) | 1995-09-29 | 1999-08-30 | Lilly Co Eli | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
CA2249601A1 (en) | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
WO1997038984A1 (en) | 1996-04-17 | 1997-10-23 | Du Pont Pharmaceuticals Company | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
US5869488A (en) | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5877173A (en) | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
IL128118A0 (en) | 1996-09-10 | 1999-11-30 | Thomae Gmbh Dr K | Modified amino acids medicaments containing these compounds and processes for their preparation |
DE19643331A1 (de) | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
HUP0001285A3 (en) | 1997-05-08 | 2000-10-30 | Smithkline Beecham Corp Philap | Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them |
US6214846B1 (en) * | 1997-06-27 | 2001-04-10 | Merck Sharp & Dohme Limited | Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents |
US20020163987A1 (en) * | 1997-12-12 | 2002-11-07 | British Nuclear Fuels Plc | Monitoring a sample containing a neutron source |
CA2325559A1 (en) | 1998-04-14 | 1999-10-21 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6358698B1 (en) | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
CA2315050C (en) | 1998-10-16 | 2009-02-03 | Suntory Limited | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof |
US6150393A (en) | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
WO2000056335A1 (en) | 1999-03-24 | 2000-09-28 | The Regents Of The University Of California | Methods for treating neurodegenerative disorders using aspartyl protease inhibitors |
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
HUP0201033A3 (en) | 1999-05-17 | 2003-03-28 | Novo Nordisk As | Glucagon antagonists/inverse agonists, process for their preparation and their use |
US20050148018A1 (en) | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7022698B2 (en) * | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
JP4664564B2 (ja) | 2000-03-06 | 2011-04-06 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン関連疾患の治療に使用する含窒素環式化合物 |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
DE60231209D1 (de) * | 2001-06-05 | 2009-04-02 | Toyo Boseki | Antithrombotische zusammensetzungen und diese enthaltende medizinische instrumente |
MXPA04006280A (es) | 2001-12-28 | 2004-09-27 | Acadia Pharm Inc | Compuestos espiroazaciclicos como moduladores de receptor de monoamina. |
WO2003062208A1 (en) | 2002-01-17 | 2003-07-31 | General Electric Company | Onium salts with weakly coordinating imidazolidine anion as cationic initiators |
EP1509505A2 (en) | 2002-01-23 | 2005-03-02 | Arena Pharmaceuticals, Inc. | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO |
UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
RU2320646C2 (ru) | 2002-06-24 | 2008-03-27 | Акадиа Фармасьютикалз Инк. | N-замещенные производные пиперидина в качестве агентов серотонинового рецептора |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
AU2003249983A1 (en) | 2002-07-18 | 2004-02-09 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
AU2003284899A1 (en) | 2002-10-29 | 2004-05-25 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
SG170617A1 (en) | 2003-01-16 | 2011-05-30 | Acadia Pharm Inc | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
KR20050092123A (ko) * | 2003-01-23 | 2005-09-20 | 아카디아 파마슈티칼스 인코포레이티드 | N-데스메틸클로자핀의 인간의 신경정신성 질환의 치료용도 |
DE602004002567T2 (de) | 2003-02-17 | 2007-05-31 | F. Hoffmann-La Roche Ag | Piperidinbenzolsulfonamidderivate |
US7628762B2 (en) | 2003-03-19 | 2009-12-08 | Suros Surgical Systems, Inc. | Adapter assembly for stereotactic biopsy |
WO2005063254A2 (en) * | 2003-12-22 | 2005-07-14 | Acadia Pharmaceuticals Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
US7820695B2 (en) * | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7790899B2 (en) * | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
SG157378A1 (en) * | 2004-09-27 | 2009-12-29 | Acadia Pharm Inc | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation |
-
2005
- 2005-09-26 SG SG200907436-0A patent/SG157378A1/en unknown
- 2005-09-26 JP JP2007533699A patent/JP5154227B2/ja active Active
- 2005-09-26 CN CN2005800326490A patent/CN101031548B/zh active Active
- 2005-09-26 AU AU2005289444A patent/AU2005289444B2/en active Active
- 2005-09-26 ES ES10180395.5T patent/ES2530258T3/es active Active
- 2005-09-26 JP JP2007533762A patent/JP4996467B2/ja active Active
- 2005-09-26 PL PL10180395T patent/PL2289879T3/pl unknown
- 2005-09-26 WO PCT/US2005/034376 patent/WO2006036874A1/en active Application Filing
- 2005-09-26 EP EP05801891A patent/EP1794125A1/en not_active Withdrawn
- 2005-09-26 WO PCT/US2005/034813 patent/WO2006037043A1/en active Application Filing
- 2005-09-26 PL PL05805643T patent/PL1794126T3/pl unknown
- 2005-09-26 BR BRPI0516063-4A patent/BRPI0516063A/pt not_active Application Discontinuation
- 2005-09-26 EP EP10180395.5A patent/EP2289879B1/en active Active
- 2005-09-26 MX MX2007003403A patent/MX2007003403A/es not_active Application Discontinuation
- 2005-09-26 DK DK05805643.3T patent/DK1794126T3/da active
- 2005-09-26 SG SG201002293-7A patent/SG161221A1/en unknown
- 2005-09-26 CA CA2580136A patent/CA2580136C/en active Active
- 2005-09-26 KR KR1020077009394A patent/KR101260036B1/ko active IP Right Grant
- 2005-09-26 NZ NZ553702A patent/NZ553702A/en unknown
- 2005-09-26 CN CN201110039289.4A patent/CN102153505B/zh active Active
- 2005-09-26 ES ES05805643T patent/ES2412207T3/es active Active
- 2005-09-26 CN CN2005800326503A patent/CN101035759B/zh active Active
- 2005-09-26 CA CA002580129A patent/CA2580129A1/en not_active Abandoned
- 2005-09-26 KR KR1020077009395A patent/KR20070083800A/ko not_active Application Discontinuation
- 2005-09-26 MX MX2007003433A patent/MX2007003433A/es active IP Right Grant
- 2005-09-26 US US11/235,558 patent/US7732615B2/en active Active
- 2005-09-26 EP EP05805643A patent/EP1794126B1/en active Active
- 2005-09-26 AU AU2005289635A patent/AU2005289635A1/en not_active Abandoned
- 2005-09-26 US US11/235,381 patent/US7868176B2/en active Active
- 2005-09-26 RU RU2007115886/04A patent/RU2417986C2/ru active
- 2005-09-26 RU RU2007115921/04A patent/RU2387643C2/ru active
-
2006
- 2006-05-03 US US11/417,447 patent/US20060205780A1/en not_active Abandoned
- 2006-05-03 US US11/418,341 patent/US20060205781A1/en not_active Abandoned
-
2007
- 2007-03-20 ZA ZA200702345A patent/ZA200702345B/xx unknown
- 2007-03-20 ZA ZA200702349A patent/ZA200702349B/xx unknown
- 2007-09-28 HK HK07110591.5A patent/HK1102397A1/xx unknown
-
2010
- 2010-01-29 ZA ZA201000714A patent/ZA201000714B/en unknown
- 2010-06-07 US US12/795,547 patent/US7923564B2/en active Active
-
2011
- 2011-04-06 US US13/081,427 patent/US8236960B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2289879T3 (pl) | Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu | |
WO2008144326A3 (en) | Synthesis of n-(4-fluorobenzyl)-n-(l-methylpiperidin-4-yl)-n'-(4- (2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | |
ZA200803820B (en) | Pharmaceutical salts and polymorphs of N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino) iminomethyl] benzoyl] amino]-5-meth oxy-benzamide, A factor Xa inhibitor | |
AR037460A1 (es) | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion | |
NO20050741D0 (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
NO20050985L (no) | 3-z-(1-(4-(n-((4-4metyl-piperazin-1-yl)-metylkarbonyl)- n-metyl-amino)-anilino)-1-fenyl-metylen)-6-metoksykarb onyl-2-indolinon-monoetansulfonat og anvendelse derav | |
IL189201A0 (en) | N-(arylamino)-sulfonamide inhibitors of mek | |
IL184125A (en) | Use of 3 - z - [- 1 - (4 - (n - ((4 - methyl - piperazine - 1 - yl) - methylcarbonyl) - n - methyl - amino) anilino) - 1 - phenyl - methylene] - 6 Methoxycarbonyl-2-indulinone for the preparation or prevention of osteopathic pulmonary fibrosis | |
IL190198A0 (en) | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
ZA200902469B (en) | 4-[4-({[4-Chloro-3(Trifluoromethyl)Phenyl)]Carbamoyl} Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate | |
PL2091910T3 (pl) | Postacie krystaliczne kwasu (3S)-3-[N-(N’-(2-tert-butylofenylo)oksamylo)alaninylo]amino-5-(2’,3’,5’,6’-tetrafluorofenoksy)-4-oksopentanowego | |
HK1095327A1 (en) | 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | |
HK1078315A1 (en) | Synthesis of 2-hydroxy-n,n-dimethyl-3- 2- 1(r)-(5-methyl-2-furanyl)propyl amino -3,4-dioxo-1-cyclobuten- 1-yl amino benzamide | |
MX2011007864A (es) | Isosteros para realzar la transcripcion y su uso en terapia. | |
DE602006015309D1 (de) | Haar- und/oder kopfhautpflegezusammensetzungen mit amino-oxo-indolyliden-verbindungen | |
IS2473B (is) | Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess | |
HUP0401694A3 (en) | Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use | |
IL180336A0 (en) | Crystal forms of (3r) -1 - (2 - methylalanyl - d - tryptophyl) - 3 -(phenylmethyl)-3- piperidinecarboxylic acid 1, 2, 2 - trimethylhydrazide | |
EP1896433A4 (en) | NOVEL CRYSTALLINE FORMS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOL-5-YL) BI-PHENYL-4 ylmethyl] amine | |
EP1499586A4 (en) | NEW FORM OF N- (TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL) -D-PHENYLALANINE | |
SI1794126T1 (sl) | Kristaln oblika N-(4-flurobenzil)-N-(1-metilpiperidin-4-il)-N'-(4-(2- metilpropiloksi)fenilmetil)karbamid hemi-tartrata | |
ZA200801443B (en) | N-(arylamino)-sulfonamide inhibitors of MEK | |
DE60237940D1 (de) | Methode und Gerät zum Erzeugen von optimierter Lesezeitgebung für Lese- und Schreiboffset eines magnetoresistiven Kopfes | |
DE602004028124D1 (de) | Verwendung von oberflächenspannungsreduzierenden verbindungen in einem textilbehandlungsmittel | |
EP1795526A4 (en) | N-SUBSTITUTED N- (4-PIPERIDINYL) AMIDE DERIVATIVE |